As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …

Preclinical strategies that are used to identify potential drug candidates include target-based
screening, phenotypic screening, modification of natural substances and biologic-based …

Summary Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates
insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite …

Type 2 diabetes mellitus has become an epidemic, and virtually no physician is without
patients who have the disease. Whereas insulin insensitivity is an early phenomenon partly …

Gut peptides, exemplified by glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are secreted in a nutrient-dependent manner and stimulate …

The dipeptidyl peptidase (DPP)‐4 inhibitors are a new class of antihyperglycaemic agents
which were developed for the treatment of type 2 diabetes by rational drug design, based on …

Peptides, defined as polymers of less than 50 amino acids with a molecular weight of less
than 10 kDa, represent a fast-growing class of new therapeutics which has unique …

Incretin-based drugs, such as glucagon-like peptide-1 receptor agonists and dipeptidyl
peptidase 4 inhibitors, are now routinely used to treat type 2 diabetes mellitus. These agents …

Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent
does not generally provide durable glycaemic control over the long term. Sulphonylurea …

There is a progressive deterioration in β-cell function and mass in type 2 diabetics. It was
found that islet function was about 50% of normal at the time of diagnosis, and a reduction in …